341,889 Shares of SOPHiA GENETICS SA $SOPH Acquired by Sowell Financial Services LLC

Key Points

• Sowell Financial Services acquired 341,889 SOPHiA GENETICS shares worth approximately $2.87 million, giving it a 0.41% stake. Institutional investors collectively own 31.59% of the company.
• SOPH shares opened at $7.63, down 4.3%, with a market capitalization of roughly $640 million. The company reported a quarterly loss of $0.26 per share, missing estimates, despite revenue of $23.31 million exceeding expectations.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $10 price target; meanwhile, insiders have sold 250,662 shares worth $1.94 million over the past three months.

Sowell Financial Services LLC acquired a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 341,889 shares of the company's stock, valued at approximately $2,865,000. Sowell Financial Services LLC owned approximately 0.41% of SOPHiA GENETICS at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SOPH. Principal Financial Group Inc. grew its holdings in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the 1st quarter worth $50,000. Royal Bank of Canada increased its holdings in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new position in shares of SOPHiA GENETICS in the second quarter valued at approximately $119,000. Finally, Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS during the second quarter valued at $567,000. Institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Stock Down 4.3%

SOPH stock opened at $7.63 on Friday. The stock has a 50-day simple moving average of $7.87 and a two-hundred day simple moving average of $5.95. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $640.12 million, a PE ratio of -6.63 and a beta of 0.95. SOPHiA GENETICS SA has a twelve month low of $3.83 and a twelve month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Zhenyu Xu sold 17,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares of the company's stock, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Jurgi Camblong sold 40,172 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $326,598.36. Following the completion of the sale, the chairman directly owned 3,395,650 shares of the company's stock, valued at $27,606,634.50. The trade was a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 250,662 shares of company stock valued at $1,942,499 over the last three months. 4.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on SOPH shares. Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a report on Monday, October 12th. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $10.00.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company's primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.